Ilyang Pharmaceutical Co., Ltd.

As of June 30, 2026, Ilyang Pharmaceutical Co., Ltd.Pfd Registered Shs Non-Voting maintains a current ratio of 0.88, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 40.35, indicating elevated leverage, while an interest coverage ratio of -2.44 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Ilyang Pharmaceutical Co., Ltd.Pfd Registered Shs Non-Voting posted a return on equity (ROE) of 7.10, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -2.98, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 3.86, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.23, useful for judging operating efficiency across full business cycles. The company generates approximately 417.51M in revenue per employee across its workforce of 665.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.39 indicates how many times Ilyang Pharmaceutical Co., Ltd.Pfd Registered Shs Non-Voting sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Ilyang Pharmaceutical Co., Ltd.Pfd Registered Shs Non-Voting recorded 5.20B in income tax expense. That works out to an effective tax rate of 23.04, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 22.56B, leaving 17.29B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Ilyang Pharmaceutical Co., Ltd.Pfd Registered Shs Non-Voting's stock has declined approximately 45.30% over the past 52 weeks. The 50-day moving average sits at 7,813.00, while the 200-day moving average is 10,048.75.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -5.26B, while operating income came in at -13.73B.

As of June 30, 2026, Ilyang Pharmaceutical Co., Ltd.Pfd Registered Shs Non-Voting holds 17.74B in cash and equivalents against 103.67B in total debt, resulting in a net debt position of 90.27B. Total book value stands at 252.31B, with working capital of -19.02B providing operational flexibility.

Ilyang Pharmaceutical Co., Ltd.Pfd Registered Shs Non-Voting produced 34.49B in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Ilyang Pharmaceutical Co., Ltd.Pfd Registered Shs Non-Voting posted a gross margin of 39.55, reflecting its pricing power and cost economics. The operating margin of -4.94 and net profit margin of 6.22 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of 18.71 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

Ilyang Pharmaceutical Co., Ltd.Pfd Registered Shs Non-Voting's most recent stock split took place on July 7, 2006 with a 1:2 split ratio.